deSouza, N. M., Liu, Y., Chiti, A., Oprea-Lager, D., Gebhart, G., Van Beers, B. E., Herrmann, K., Lecouvet, F. E. (2018) Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group. EUROPEAN JOURNAL OF CANCER, 91. pp. 153-163. ISSN 0959-8049

Full text not available from this repository.

Abstract

Patients with oligometastatic disease (OMD) often have controllable symptoms, and cures are possible. Technical improvements in surgery and radiotherapy have introduced the option of metastasis-directed ablative therapies as an adjunct or alternative to standard-of-care systemic therapies. Several clinical trials and registries are investigating the benefit of these therapeutic approaches across several cancer sites. This requires that patients are correctly included and followed with appropriate imaging. This article discusses the evidence and offers recommendations for the implementation of standard-of-care (Response Evaluation Criteria in Solid Tumours measurements on computed tomography [CT], magnetic resonance imaging [MRI] and bone scintigraphy) and advanced imaging modalities (functional, metabolic and radionuclide targeted) for identifying and following up patients with OMD. Imaging requirements for recognising OMD vary with tumour type, metastatic location, and timing of measurement in relation to previous treatment. At each point in the disease cycle (diagnosis, response assessment and follow-up), imaging must be tailored to the clinical question and the context of prior treatment. The differential use of whole-body approaches such as F-18-FDG-positron emission tomography (PET)/CT, diffusion-weighted MRI, F-18-Choline-PET/CT and Ga-68-prostate specific membrane antigen-PET/CT require rationalisation depending on clinical risk assessment. Optimal standardised imaging approaches will enable OMD trials to document patterns of disease progression and outcomes of treatment. Quality assured and quality controlled imaging data included in databases such as the European Organisation for Research and Treatment of Cancer Imaging platform for the Oligocare trial (a prospective, large-scale observational basket study being set up to collect outcome data from patients with OMD treated with radiation therapy) will establish a large and high-quality imaging warehouse for future research. (C) 2017 Published by Elsevier Ltd.

Item Type:	Review Article
Authors (ICR Faculty only):	Desouza, Nandita
All Authors:	deSouza, N. M., Liu, Y., Chiti, A., Oprea-Lager, D., Gebhart, G., Van Beers, B. E., Herrmann, K., Lecouvet, F. E.
Additional Information:	ISI Document Delivery No.: FU6XD Times Cited: 0 Cited Reference Count: 88 deSouza, Nandita M. Liu, Yan Chiti, Arturo Oprea-Lager, Daniela Gebhart, Geraldine Van Beers, Bernard E. Herrmann, Ken Lecouvet, Frederic E. EORTC cancer research fund The authors are extremely grateful to Dr. Margarita Kirienko, (Humanitas University) for her contribution to the research and input on the lung cancer imaging section, to Yolande Lievens for sharing information on Oligocare and providing useful comments on the manuscript and to Prof Bertrand Tombal for his useful comments for improving the final draft of the manuscript. They also thank the EORTC cancer research fund. 0 Elsevier sci ltd Oxford 1879-0852
Uncontrolled Keywords:	Oligometastases Magnetic resonance imaging Computed tomography Positron emission tomography Molecular imaging Lung cancer Prostate cancer Breast cancer Gastrointestinal cancer cell lung-cancer positron-emission-tomography whole-body mri risk prostate-cancer fdg-pet-ct colorectal liver metastases breast-cancer diagnostic-accuracy f-18-fdg pet/ct interobserver agreement Oncology
Research teams:	ICR divisions > Radiotherapy and Imaging > Magnetic Resonance
Depositing User:	Barry Jenkins
Date Deposited:	19 Feb 2018 15:05
Last Modified:	19 Feb 2018 15:05
URI:	http://publications.icr.ac.uk/id/eprint/16615

Actions (login required)

View Item